OB:ABT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Aqua Bio Technology

Executive Summary

Aqua Bio Technology ASA engages in developing and commercializing active ingredients for use in skin care products in Norway. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Aqua Bio Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.7%

ABT

-0.4%

NO Chemicals

-1.9%

NO Market


1 Year Return

221.8%

ABT

10.1%

NO Chemicals

-12.5%

NO Market

Return vs Industry: ABT exceeded the Norwegian Chemicals industry which returned 10.1% over the past year.

Return vs Market: ABT exceeded the Norwegian Market which returned -12.5% over the past year.


Shareholder returns

ABTIndustryMarket
7 Day-0.7%-0.4%-1.9%
30 Day11.2%-0.1%-2.7%
90 Day79.1%8.9%6.0%
1 Year221.8%221.8%13.6%10.1%-9.6%-12.5%
3 Year-21.7%-21.7%10.0%-0.7%6.7%-5.5%
5 Year-47.5%-61.2%48.7%26.3%50.1%19.9%

Price Volatility Vs. Market

How volatile is Aqua Bio Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aqua Bio Technology undervalued compared to its fair value and its price relative to the market?

116.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABT is unprofitable, so we can't compare its PE Ratio to the XE Chemicals industry average.

PE vs Market: ABT is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABT is overvalued based on its PB Ratio (116x) compared to the XE Chemicals industry average (1.6x).


Next Steps

Future Growth

How is Aqua Bio Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aqua Bio Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Aqua Bio Technology performed over the past 5 years?

-54.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABT is currently unprofitable.

Growing Profit Margin: ABT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABT is unprofitable, and losses have increased over the past 5 years at a rate of 54.9% per year.

Accelerating Growth: Unable to compare ABT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABT is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-11.8%).


Return on Equity

High ROE: ABT has a negative Return on Equity (-1194.42%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aqua Bio Technology's financial position?


Financial Position Analysis

Short Term Liabilities: ABT's short term assets (NOK3.7M) exceed its short term liabilities (NOK3.1M).

Long Term Liabilities: ABT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: ABT's debt to equity ratio (145.9%) is considered high.

Reducing Debt: ABT's debt to equity ratio has increased from 7.9% to 145.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABT has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ABT is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Aqua Bio Technology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ABT is not paying a notable dividend for the Norwegian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABT's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average board tenure


CEO

Espen Kvale (44 yo)

1.67yrs

Tenure

Mr. Espen Østhagen Kvale serves as the Chief Executive Officer at Aqua Bio Technology ASA since July 1, 2020 and served as its Interim Chief Executive Officer from January 2019 to July 1, 2020. He served a ...


CEO Compensation Analysis

Compensation vs Market: Espen's total compensation ($USD0.00) is below average for companies of similar size in the Norwegian market ($USD376.81K).

Compensation vs Earnings: Espen's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Tone Bjornov
Director12.17yrskr147.50k0.11%
NOK 135.0k
Roger Hofseth
Director1.67yrsno datano data
Edvard Cock
Chairman of the Board4.67yrskr285.00k5.44%
NOK 7.0m
Kristian Aase
Director5.67yrskr147.50kno data
Jan Hakan Pettersson
Director5.67yrskr147.50kno data

5.7yrs

Average Tenure

59yo

Average Age

Experienced Board: ABT's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23%.


Top Shareholders

Company Information

Aqua Bio Technology ASA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aqua Bio Technology ASA
  • Ticker: ABT
  • Exchange: OB
  • Founded: 2000
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: kr127.787m
  • Shares outstanding: 18.39m
  • Website: https://www.aquabiotechnology.com

Location

  • Aqua Bio Technology ASA
  • Fornebuveien 37
  • Lysaker
  • Akershus
  • 1366
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABTOB (Oslo Bors)YesOrdinary SharesNONOKJan 2008
0I8CLSE (London Stock Exchange)YesOrdinary SharesGBNOKJan 2008
ABTOBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBNOKJan 2008

Biography

Aqua Bio Technology ASA engages in developing and commercializing active ingredients for use in skin care products in Norway. It offers Aquabeautine XL, a proprietary ingredient; and Spirulysat, an antioxi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 05:13
End of Day Share Price2020/09/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.